Virbac Shares Climb to €369, TP Icap Raises Target to €412
Midday sees the Carros veterinary laboratory up by 2.5% at €369 in a well-oriented Parisian market. The SBF 120 concurrently rises by 0.41%. The stock is among the top gainers in the broad index.
TP Icap Midcap Raises Target to €412 and Reaffirms Buy Recommendation
On May 21, TP Icap Midcap raised its price target on Virbac from €407 to €412, while maintaining its buy opinion. Based on the current price of €369, this new target implies a potential upside of nearly 11.7%. This revision follows the stock's 8.21% recovery over the week and a year-to-date gain of 18.08%. The session's rebound extends the movement that began after defending the moving average, in a previous session where the stock gained 2.75% to €355.
Price Moves Above Its Three Moving Averages, Targeting €384 Resistance
At €369, the stock is now trading above its three moving averages: MM20 at €361.75, MM50 at €356.68, and MM200 at €347.37, marking a 6.23% increase from the latter. This setup confirms the exit from the consolidation phase observed at the beginning of May. The RSI at 51 remains neutral, allowing room for growth before any overbought signal. The next identified level in the data is the €384 resistance, about 4% from the current price. The one-month volatility is measured at 7.40%. The stock maintains a positive momentum over the last three months, slightly up (+0.14%), but bolstered by the recent session rebounds.
